Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 153-160

  Smith, Lachlan J ^a   Baldo, Guilherme ^b,d   Wu, Susan ^b   Liu, Yuli ^b   Whyte, Michael P ^b,c   Giugliani, Roberto ^d   Elliott, Dawn M ^a,e   Haskins, Mark E ^f   Ponder, Katherine P ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (United States)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e University of Delaware   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone; Cathepsin; Inflammation; Intervertebral disk; Lumbar spine; Mucopolysaccharidosis VII

Indexed keywords

CATHEPSIN B; CATHEPSIN K; COLLAGEN TYPE 2; TOLL LIKE RECEPTOR 4;

ADULT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERVERTEBRAL DISK; LUMBAR SPINE DISEASE; MALE; MORPHOLOGY; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; NUCLEUS PULPOSUS; PATHOGENESIS; PRIORITY JOURNAL; SPINE DISEASE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CATHEPSINS; CYTOKINES; DISEASE MODELS, ANIMAL; DOGS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; MATRIX METALLOPROTEINASES; MUCOPOLYSACCHARIDOSIS VII; RNA, MESSENGER; SPINAL DISEASES;

CANIS FAMILIARIS;

EID: 84866155359     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.03.014     Document Type: Article

References (44)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Wraith J.E. The mucopolysaccharidoses: a clinical review and guide to management. Arch. Dis. Child. 1995, 72:263-267.
3. White K.K., Harmatz P. Orthopedic management of mucopolysaccharide disease. J. Pediatr. Rehabil. Med. 2010, 3:47-56.
4. Sly W.S., Quinton B.A., McAlister W.H., Rimoin D.L. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J. Pediatr. 1973, 82:249-257.
5. Vogler C., Levy B., Kyle J.W., Sly W.S., Williamson J., Whyte M.P. Mucopolysaccharidosis VII: postmortem biochemical and pathological findings in a young adult with beta-glucuronidase deficiency. Mod. Pathol. 1994, 7:132-137.
6. Pizzutillo P.D., Osterkamp J.A., Scott C.I., Lee M.S. Atlantoaxial instability in mucopolysaccharidosis type VII. J. Pediatr. Orthop. 1989, 9:76-78.
7. Beaudet A.L., DiFerrante N.M., Ferry G.D., Nichols B.L., Mullins C.E. Variation in the phenotypic expression of beta-glucuronidase deficiency. J. Pediatr. 1975, 86:388-394.
8. Dickerman R.D., Colle K.O., Bruno C.A., Schneider S.J. Craniovertebral instability with spinal cord compression in a 17-month-old boy with Sly syndrome (mucopolysaccharidosis type VII): a surgical dilemma. Spine 2004, 29:E92-E94.
9. de Kremer R.D., Givogri I., Argarana C.E., Hliba E., Conci R., Boldini C.D., Capra A.P. Mucopolysaccharidosis type VII (beta-glucuronidase deficiency): a chronic variant with an oligosymptomatic severe skeletal dysplasia. Am. J. Med. Genet. 1992, 44:145-152.
10. Ray J., Bouvet A., DeSanto C., Fyfe J.C., Xu D., Wolfe J.H., Aguirre G.D., Patterson D.F., Haskins M.E., Henthorn P.S. Cloning of the canine beta-glucuronidase cDNA, mutation identification in canine MPS VII, and retroviral vector-mediated correction of MPS VII cells. Genomics 1998, 48:248-253.
11. Haskins M., Casal M., Ellinwood N.M., Melniczek J., Mazrier H., Giger U. Animal models for mucopolysaccharidoses and their clinical relevance. Acta Paediatr. Suppl. 2002, 91:88-97.
12. Haskins M.E., Desnick R.J., DiFerrante N., Jezyk P.F., Patterson D.F. Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII. Pediatr. Res. 1984, 18:980-984.
13. Silverstein Dombrowski D.C., Carmichael K.P., Wang P., O'Malley T.M., Haskins M.E., Giger U. Mucopolysaccharidosis type VII in a German Shepherd Dog. J. Am. Vet. Med. Assoc. 2004, 224:553-557.
14. Smith L.J., Martin J.T., Szczesny S.E., Ponder K.P., Haskins M.E., Elliott D.M. Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII. J. Orthop. Res. 2010, 28:616-622.
15. Metcalf J.A., Linders B., Wu S., Bigg P., O'Donnell P., Sleeper M.M., Whyte M.P., Haskins M., Ponder K.P. Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol. Genet. Metab. 2010, 99:396-407.
16. Baldo G., Wu S., Howe R.A., Ramamoothy M., Knutsen R.H., Fang J., Mecham R.P., Liu Y., Wu X., Atkinson J.P., Ponder K.P. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol. Genet. Metab. 2011, 104:608-619.
17. McGrath M.E. The lysosomal cysteine proteases. Annu. Rev. Biophys. Biomol. Struct. 1999, 28:181-204.
18. Simonaro C.M. Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation. J. Pediatr. Rehabil. Med. 2010, 3:85-88.
19. Simonaro C.M., D'Angelo M., Haskins M.E., Schuchman E.H. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res. 2005, 57:701-707.
20. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., Schuchman E.H. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 2008, 172:112-122.
21. Johnson G.B., Brunn G.J., Kodaira Y., Platt J.L. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 2002, 168:5233-5239.
22. Ausseil J., Desmaris N., Bigou S., Attali R., Corbineau S., Vitry S., Parent M., Cheillan D., Fuller M., Maire I., Vanier M.T., Heard J.M. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One 2008, 3:e2296.
23. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:222-227.
24. Herati R.S., Knox V.W., O'Donnell P., D'Angelo M., Haskins M.E., Ponder K.P. Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol. Genet. Metab. 2008, 95:142-151.
25. Smith L.J., Fazzalari N.L. The elastic fibre network of the human lumbar anulus fibrosus: architecture, mechanical function and potential role in the progression of intervertebral disc degeneration. Eur. Spine J. 2009, 18:439-448.
26. Urban J. Disc biochemistry in relation to function. The Lumbar Spine 1996, 271-280. Saunders, Philadelphia. S.W. Wiesel, J.N. Weinstein, H.N. Herkowitz, J. Dvorak, G. Bell (Eds.).
27. Singh K., Masuda K., Thonar E.J., An H.S., Cs-Szabo G. Age-related changes in the extracellular matrix of nucleus pulposus and anulus fibrosus of human intervertebral disc. Spine (Phila Pa 1976) 2009, 34:10-16.
28. Brown S., Melrose J., Caterson B., Roughley P., Eisenstein S.M., Roberts S. A comparative evaluation of the small leucine-rich proteoglycans of pathological human intervertebral discs. Eur. Spine J. 2012, 10.1007/s00586-012-2179-1.
29. Hou W.S., Li Z., Buttner F.H., Bartnik E., Bromme D. Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol. Chem. 2003, 384:891-897.
30. Mort J.S., Magny M.C., Lee E.R. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. Biochem. J. 1998, 335(Pt. 3):491-494.
31. Dejica V.M., Mort J.S., Laverty S., Percival M.D., Antoniou J., Zukor D.J., Poole A.R. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am. J. Pathol. 2008, 173:161-169.
32. Novinec M., Grass R.N., Stark W.J., Turk V., Baici A., Lenarcic B. Interaction between human cathepsins K, L, and S and elastins: mechanism of elastinolysis and inhibition by macromolecular inhibitors. J. Biol. Chem. 2007, 282:7893-7902.
33. Solau-Gervais E., Zerimech F., Lemaire R., Fontaine C., Huet G., Flipo R.M. Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. Scand. J. Rheumatol. 2007, 36:373-377.
34. Ma X., Tittiger M., Knutsen R.H., Kovacs A., Schaller L., Mecham R.P., Ponder K.P. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol. Genet. Metab. 2008, 94:298-304.
35. Li Z., Yasuda Y., Li W., Bogyo M., Katz N., Gordon R.E., Fields G.B., Bromme D. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J. Biol. Chem. 2004, 279:5470-5479.
36. Gruber H.E., Ingram J.A., Hoelscher G.L., Zinchenko N., Norton H.J., Hanley E.N. Constitutive expression of cathepsin K in the human intervertebral disc: new insight into disc extracellular matrix remodeling via cathepsin K and receptor activator of nuclear factor-kappaB ligand. Arthritis Res. Ther. 2011, 13:R140.
37. Ariga K., Yonenobu K., Nakase T., Kaneko M., Okuda S., Uchiyama Y., Yoshikawa H. Localization of cathepsins D, K, and L in degenerated human intervertebral discs. Spine (Phila Pa 1976) 2001, 26:2666-2672.
38. Wilson S., Hashamiyan S., Clarke L., Saftig P., Mort J., Dejica V.M., Bromme D. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am. J. Pathol. 2009, 175:2053-2062.
39. Kalamajski S., Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. 2010, 29:248-253.
40. Hopkins P.A., Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin. Exp. Immunol. 2005, 140:395-407.
41. Sloane J.A., Blitz D., Margolin Z., Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromolecular Med. 2010, 12:149-163.
42. Zhang Z., Schluesener H.J. Mammalian Toll-like receptors: from endogenous ligands to tissue regeneration. Cell. Mol. Life Sci. 2006, 63:2901-2907.
43. Tsan M.F., Gao B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 2004, 76:514-519.
44. Peri F., Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol. Adv. 2011, 30(1):251-260.